Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

被引:0
|
作者
Michael E. Thase
Arielle D. Stanford
Asli Memisoglu
William Martin
Amy Claxton
J. Alexander Bodkin
Madhukar H. Trivedi
Maurizio Fava
Miao Yu
Sanjeev Pathak
机构
[1] University of Pennsylvania School of Medicine,Department of Psychiatry, Perelman School of Medicine
[2] Alkermes,undefined
[3] Inc.,undefined
[4] McLean Hospital,undefined
[5] Harvard Medical School,undefined
[6] University of Texas Southwestern Medical Center,undefined
[7] Massachusetts General Hospital,undefined
来源
Neuropsychopharmacology | 2019年 / 44卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). FORWARD-2, an open-label extension study, assessed long-term safety and tolerability of adjunctive BUP/SAM treatment in these patients. Patients from four short-term trials and de novo patients were enrolled; all had confirmed MDD and a current major depressive episode lasting 2–24 months. Patients were treated with an established ADT for ≥8 weeks before receiving sublingual, adjunctive BUP/SAM 2 mg/2 mg for up to 52 weeks. Safety (primary objective) was assessed via adverse events (AEs), the Columbia-Suicide Severity Rating Scale, and the Clinical Opiate Withdrawal Scale (COWS). Exploratory evaluation of efficacy was done using the Montgomery–Åsberg Depression Rating Scale (MADRS). Of 1485 patients, 50% completed the study and 11% discontinued due to AEs. AEs of nausea, headache, constipation, dizziness, and somnolence, each occurred in ≥10% of patients. There was no evidence of increased suicidal ideation or behavior. Euphoria-related AEs were uncommon (1.2%). Following abrupt BUP/SAM discontinuation, “drug withdrawal” AEs were infrequent (0.4%), and the incidence of COWS categorical worsening after abrupt drug discontinuation was low (6.5%). Improvements in mean MADRS scores were maintained until study end, suggesting durability of antidepressant effect in patients continuing treatment. BUP/SAM was generally well tolerated, with a low risk of abuse and an AE profile consistent with those seen in placebo-controlled studies. Withdrawal reports were uncommon and of limited clinical impact.
引用
收藏
页码:2268 / 2276
页数:8
相关论文
共 50 条
  • [31] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [32] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [33] ALKS 5461 (a Buprenorphine-Samidorphan Combination) for Adjunctive Treatment of Major Depressive Disorder: Results From Analyses of US Patients From Three Independent Placebo-Controlled Trials
    Fava, Maurizio
    Thase, Michael
    Trivedi, Madhukar
    Pathak, Sanjeev
    Stanford, Arielle
    Memisoglu, Asli
    Martin, William
    Claxton, Amy
    Ehrich, Elliot
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S524 - S526
  • [34] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2390 - I2392
  • [35] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [36] Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
    Rajnish Mago
    Giovanna Forero
    William M. Greenberg
    Carl Gommoll
    Changzheng Chen
    Clinical Drug Investigation, 2013, 33 : 761 - 771
  • [37] Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
    Mago, Rajnish
    Forero, Giovanna
    Greenberg, William M.
    Gommoll, Carl
    Chen, Changzheng
    CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 761 - 771
  • [38] Safety and tolerability of levomilnacipran SR in major depressive disorder: results from an open-label, 48-week extension study
    Mago, R.
    Forero, G.
    Greenberg, W. M.
    Gommoll, C.
    Chen, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S330 - S330
  • [39] LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
    Ketter, Terence A.
    Sarma, Kaushik
    Silva, Robert
    Kroger, Hans
    Cucchiaro, Josephine
    Loebel, Antony
    DEPRESSION AND ANXIETY, 2016, 33 (05) : 424 - 434
  • [40] TOPIRAMATE AS ADJUNCTIVE THERAPY IN PATIENTS WITH REFRACTORY EPILEPSY - A REPORT OF A LONG-TERM, OPEN-LABEL STUDY
    COWELL, PG
    COLES, HJ
    CRAWFORD, PM
    EPILEPSIA, 1995, 36 : S152 - S152